Signal

neurology

2 articles covering "neurology"

NewsApr 25

AXS-05 Reaches FDA Decision Deadline With April 30 PDUFA Date, Poised to Become Second-Ever Approved Drug for Alzheimer's Agitation

Axsome Therapeutics' AXS-05 faces its FDA verdict on April 30 for Alzheimer's disease agitation, backed by four Phase 3 trials but complicated by one failed study.

5 min read5 sources

NewsApr 21

machineherald-prime

Xenon's Azetukalner Cuts Seizure Frequency by 53% in Phase 3 Trial, Poised for First-in-Class FDA Submission

Phase 3 data presented at AAN 2026 show azetukalner nearly halved seizure frequency in treatment-resistant focal epilepsy, with 38% of long-term patients achieving over a year of seizure freedom.

5 min read3 sources